|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Z, Wijk N and Fong KM: Update in lung
cancer: Prologue to a modern review series. Respirology.
20:183–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Dowd EL and Baldwin DR: Early diagnosis
pivotal to survival in lung cancer. Practitioner. 258(21–24): 2–3.
2014.
|
|
4
|
Sharma SP: New therapeutic target for
non-small-cell lung cancer. Lancet Oncol. 15:e5332014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang T, Li H, Thakur A, Chen T, Xue J, Li
D and Chen M: FOXP4 modulates tumor growth and independently
associates with miR-138 in non-small cell lung cancer cells. Tumour
Biol. 36:8185–8191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cuiffo BG and Karnoub AE: Silencing FOXP2
in breast cancer cells promotes cancer stem cell traits and
metastasis. Mol Cell Oncol. 3:e10190222015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feng J, Zhang X, Zhu H, Wang X, Ni S and
Huang J: High expression of FoxP1 is associated with improved
survival in patients with non-small cell lung cancer. Am J Clin
Pathol. 138:230–235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu H, Li W, Yu X, Gao F, Duan Z, Ma X,
Tan S, Yuan Y, Liu L, Wang J, et al: EZH2-mediated Puma gene
repression regulates non-small cell lung cancer cell proliferation
and cisplatin-induced apoptosis. Oncotarget. 7:56338–56354.
2016.PubMed/NCBI
|
|
9
|
Jin J, Zhan P, Katoh M, Kobayashi SS, Phan
K, Qian H, Li H, Wang X, Wang X and Song Y: written on behalf of
the AME Lung Cancer Collaborative Group: Prognostic significance of
β-catenin expression in patients with non-small cell lung cancer: A
meta-analysis. Transl Lung Cancer Res. 6:97–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zell JA, Ou Ignatius SH, Ziogas A and
Anton-Culver H: Validation of the proposed International
Association for the Study of Lung Cancer non-small cell lung cancer
staging system revisions for advanced bronchioloalveolar carcinoma
using data from the California Cancer Registry. J Thorac Oncol.
2:1078–1085. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Palamaro L, Romano R, Fusco A, Giardino G,
Gallo V and Pignata C: FOXN1 in organ development and human
diseases. Int Rev Immunol. 33:83–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mittal V: Epithelial mesenchymal
transition in aggressive lung cancers. Adv Exp Med Biol. 890:37–56.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu C, Hou Z, Zhan P, Zhao W, Chang C, Zou
J, Hu H, Zhang Y, Yao X, Yu L and Yan J: EZH2 regulates cancer cell
migration through repressing TIMP-3 in non-small cell lung cancer.
Med Oncol. 30:7132013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Geng J, Li X, Zhou Z, Wu CL, Dai M and Bai
X: EZH2 promotes tumor progression via regulating VEGF-A/AKT
signaling in non-small cell lung cancer. Cancer Lett. 359:275–287.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Behrens C, Solis LM, Lin H, Yuan P, Tang
X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, et al: EZH2
protein expression associates with the early pathogenesis, tumor
progression, and prognosis of non-small cell lung carcinoma. Clin
Cancer Res. 19:6556–6565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou W, Wang J, Man WY, Zhang QW and Xu
WG: siRNA silencing EZH2 reverses cisplatin-resistance of human
non-small cell lung and gastric cancer cells. Asian Pac J Cancer
Prev. 16:2425–2430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu Z, Tang J, Wang J, Duan G, Zhou L and
Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and
enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS
One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang HJ, Zhang H, Zhao M, Lv Z, Zhang X,
Qin X, Wang H, Wang S, Su J, Lv X, et al: MiR-138 inhibits tumor
growth through repression of EZH2 in non-small cell lung cancer.
Cell Physiol Biochem. 31:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang D, Ding L, Wang L, Zhao Y, Sun Z,
Karnes RJ, Zhang J and Huang H: LncRNA MALAT1 enhances oncogenic
activities of EZH2 in castration-resistant prostate cancer.
Oncotarget. 6:41045–41055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim Y, Jin D, Lee BB, Cho EY, Han J, Shim
YM, Kim HK and Kim DH: Overexpression of β-catenin and cyclin D1 is
associated with poor overall survival in patients with stage IA-IIA
squamous cell lung cancer irrespective of adjuvant chemotherapy. J
Thorac Oncol. 11:2193–2201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Z, Luo Z, Zhou L, Li X, Jiang T and
Fu E: DDX5 promotes proliferation and tumorigenesis of
non-small-cell lung cancer cells by activating β-catenin signaling
pathway. Cancer Sci. 106:1303–1312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen CC, Chen HY, Su KY, Hong QS, Yan BS,
Chen CH, Pan SH, Chang YL, Wang CJ, Hung PF, et al: Shisa3 is
associated with prolonged survival through promoting β-catenin
degradation in lung cancer. Am J Respir Crit Care Med. 190:433–444.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moon RT, Kohn AD, De Ferrari GV and Kaykas
A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev
Genet. 5:691–701. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tseng RC, Lin RK, Wen CK, Tseng C, Hsu HS,
Hsu WH and Wang YC: Epigenetic silencing of AXIN2/betaTrCP and
deregulation of p53-mediated control lead to wild-type beta-catenin
nuclear accumulation in lung tumorigenesis. Oncogene. 27:4488–4496.
2008. View Article : Google Scholar : PubMed/NCBI
|
